1256667-60-3 Usage
Uses
Used in Medicinal Chemistry:
(3S)-1-(3-oxetanyl)-3-PyrrolidinaMine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structural features, including the oxetane ring and amine functional group, make it a promising candidate for the development of new drugs with potential therapeutic applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (3S)-1-(3-oxetanyl)-3-PyrrolidinaMine is utilized as a key component in the research and development of novel therapeutic agents. Its potential biological activities and structural properties allow researchers to explore its use in the treatment of various diseases and conditions, enhancing the discovery of innovative medications.
Note: Since the provided materials do not specify particular applications or industries for (3S)-1-(3-oxetanyl)-3-PyrrolidinaMine, the uses listed above are general and based on the compound's potential in medicinal chemistry and pharmaceutical research. Further research and development would be necessary to identify specific applications and industries where (3S)-1-(3-oxetanyl)-3-PyrrolidinaMine could be effectively utilized.
Check Digit Verification of cas no
The CAS Registry Mumber 1256667-60-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,6,6 and 7 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1256667-60:
(9*1)+(8*2)+(7*5)+(6*6)+(5*6)+(4*6)+(3*7)+(2*6)+(1*0)=183
183 % 10 = 3
So 1256667-60-3 is a valid CAS Registry Number.
1256667-60-3Relevant articles and documents
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 121; 148, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
